These guys are running gevo as a piggy back for themselves.They after 2 years of testing are still testing.Its a big scam this stock will be in the 1.20s tomm.good news is falc is heading over 2.00 on all the insider buying
Which if we now gevo 6 months from now they still be testing.The company im pretty sure after listening to the conference call is a insider milk it company and will cont to bleed out.Strong Sell
Conference call old gevo back to its lies and half truths.Guess what, their still testing and their burning thru money very fast.I see gevo at 1.00 very soon
Sentiment: Strong Sell
Whens the auction for the assets.Congrats for being so smart current crop.Their have been a couple crops before you so their will be plenty of company on the boards to whine when the turd finally gets laid to rest. weeeeeeee were going BK!
But now investors know what it will cost to get the trial complete.They might run this one up into a share offer.Maybe 1.50s are coming very soon. Dvax also remains a take over target
Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.
Inuvo, Inc. has entered into Amendment #8 to its Yahoo! Publisher Network Contract. The Amendment extends the term of the contract to April 24, 2015. Inuvo believes that the amended agreement, taken as a whole, is comparable to Inuvo's previously existing agreement with Yahoo!.
Also on September 25, 2013, the Company received from Tonaquint a Notice of Disposition of Collateral advising of Tonaquint's intent to sell all assets of the Company at a public auction on November 4, 2013 at 11:00 a.m. PST at 1857 Helm Drive, Las Vegas, Nevada, 89119. The Company disagrees with Tonaquint's allegations as set forth above and in the Complaint and does not believe Tonaquint is entitled to the above-referenced relief. The Company intends to vigorously defend itself against Tonaquint's attempt to sell these assets, as well as Defendants' counterclaims in general, and will continue to take legal action to protect the interests of the Company and its shareholders.
Baker Bros. Advisors also started a new position in IDRA of 4.5 MM shares - equivalent to a $7.9 MM investment in the company.
Idera's flagship development program is for a Toll-like receptor (TLR) 7, 8, and 9 antagonist IMO-8400, which is being developed as a treatment for plaque psoriasis. The company released Phase I data for this therapeutic earlier in the year, which showed that the drug was well tolerated by patients at all doses.
TLR receptors target a number of cell-signaling molecules (cytokines) that activate the immune system. The company believes that there is clear potential for indication expansion given that IMO-8400 sees efficacy against psoriasis, since many autoimmune diseases are similar and have overlap with one another in terms of treatment options. Lupus is one of many other serious autoimmune diseases that may be targeted by IMO-8400.
Phase II trial data should be available as early as Q1 2014.